Nuveen’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-772,592
| Closed | -$40.7M | – | 3845 |
|
|
2026
Q1 | $40.7M | Sell |
772,592
-305,565
| -28% | -$12.6M | 0.01% | 745 |
|
|
2025
Q4 | $43.6M | Sell |
1,078,157
-395,214
| -27% | -$9.13M | 0.01% | 713 |
|
|
2025
Q3 | $11.1M | Buy |
1,473,371
+292,843
| +25% | +$1.87M | ﹤0.01% | 1489 |
|
|
2025
Q2 | $4.4M | Sell |
1,180,528
-225,373
| -16% | -$704K | ﹤0.01% | 1941 |
|
|
2025
Q1 | $3.88M | Sell |
1,405,901
-1,228,017
| -47% | -$5.01M | ﹤0.01% | 2047 |
|
|
2024
Q4 | $14.6M | Buy |
2,633,918
+617,009
| +31% | +$4.18M | ﹤0.01% | 1368 |
|
|
2024
Q3 | $16.8M | Buy |
2,016,909
+1,269,467
| +170% | +$10.4M | ﹤0.01% | 1301 |
|
|
2024
Q2 | $5.09M | Buy |
747,442
+587,870
| +368% | +$3.56M | ﹤0.01% | 1945 |
|
|
2024
Q1 | $1.05M | Buy |
159,572
+2,940
| +2% | +$19.2K | ﹤0.01% | 2689 |
|
|
2023
Q4 | $1.02M | Buy |
156,632
+37,952
| +32% | +$201K | ﹤0.01% | 2729 |
|
|
2023
Q3 | $597K | Sell |
118,680
-57,458
| -33% | -$365K | ﹤0.01% | 2784 |
|
|
2023
Q2 | $1.54M | Buy |
+176,138
| New | +$2.05M | ﹤0.01% | 2474 |
|
|
2022
Q2 | – | Sell |
-14,237
| Closed | -$43K | – | 3474 |
|
|
2022
Q1 | $43K | Hold |
14,237
| – | – | ﹤0.01% | 3280 |
|
|
2021
Q4 | $83K | Hold |
14,237
| – | – | ﹤0.01% | 3289 |
|
|
2021
Q3 | $150K | Hold |
14,237
| – | – | ﹤0.01% | 3297 |
|
|
2021
Q2 | $175K | Buy |
14,237
+152
| +1% | +$2.59K | ﹤0.01% | 3257 |
|
|
2021
Q1 | $310K | Buy |
+14,085
| New | +$309K | ﹤0.01% | 3166 |
|
Other funds holding TERN
Nuveen's TERN Position: Q2 2026 in Review
Nuveen sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 772,592 shares — an estimated $40.7M sold.
Nuveen first reported a position in TERN in Q1 2021 and held it in 17 quarters. The position peaked at $43.6M in Q4 2025. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- Nuveen reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Nuveen sold 772,592 Terns Pharmaceuticals shares in Q2 2026, an estimated $40.7M.
- Nuveen first reported a position in Terns Pharmaceuticals in Q1 2021 and held it in 17 quarters.
- Nuveen's Terns Pharmaceuticals position peaked at $43.6M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.